CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤治疗的新方法
英文原题：Novel approaches to the treatment of multiple myeloma.
查看英文原题
Novel approaches to the treatment of multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去十年间，随着新诊断和复发/难治性多发性骨髓瘤（MM）领域新型疗法及联合方案的获批，其治疗格局已发生显著演变。诱导和维持治疗方案也转向风险适应策略，目标是为高危疾病患者实现更好的缓解率。将抗CD38单克隆抗体纳入诱导方案，已带来更长的无进展生存期和更高的可测量残留病灶阴性率。在复发背景下，B细胞成熟抗原靶向疗法的出现，包括抗体药物偶联物、CAR-T 细胞疗法，以及近期出现的双特异性抗体，已在重度经治患者中产生深度且持久的缓解。本综述文章描述了新诊断和复发/难治性背景下MM治疗的新方法。
展开英文摘要原文
The treatment landscape for multiple myeloma (MM) has evolved significantly over the last decade with the approval of novel therapies and combinations in the newly diagnosed and relapsed/refractory settings. There has also been a shift toward a risk-adapted approach to induction and maintenance regimens, with the goal of achieving better response rates for those with high-risk disease. The incorporation of anti-CD38 monoclonal antibodies into induction regimens has led to longer progression-free survival and higher rates of measurable residual disease negativity.
In the relapsed setting, the emergence of B-cell maturation antigen-directed therapy, including antibody-drug conjugates, chimeric antigen receptor T-cell therapy, and more recently, bispecific antibodies, has produced deep and durable responses in heavily pretreated patients. This review article describes novel approaches to the treatment of MM in both the newly diagnosed and the relapsed/refractory setting.
论文信息
- 作者
- Maples KT、Scott SA、Lonial S
- 单位
- Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.United States
- 文献类型
- 综述
- 期刊
- Clinical advances in hematology & oncology : H&O2023 May
- 原文标识
- PubMed 37145495